Cargando…
Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study
Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017225/ https://www.ncbi.nlm.nih.gov/pubmed/31877623 http://dx.doi.org/10.3390/cancers12010032 |
_version_ | 1783497153544454144 |
---|---|
author | Winter, Alexander Engels, Svenja Goos, Philipp Süykers, Marie-Christin Gudenkauf, Stefan Henke, Rolf-Peter Wawroschek, Friedhelm |
author_facet | Winter, Alexander Engels, Svenja Goos, Philipp Süykers, Marie-Christin Gudenkauf, Stefan Henke, Rolf-Peter Wawroschek, Friedhelm |
author_sort | Winter, Alexander |
collection | PubMed |
description | Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used in PCa. This prospective study (SentiMag Pro II, DRKS00007671) determined the diagnostic accuracy of magnetometer-guided sLND in intermediate- and high-risk PCa. Fifty intermediate- or high-risk PCa patients (prostate-specific antigen (PSA) ≥ 10 ng/mL and/or Gleason score ≥ 7; median PSA 10.8 ng/mL, IQR 7.4–19.2 ng/mL) were enrolled. After the intraprostatic SPIONs injection a day earlier, patients underwent magnetometer-guided sLND and extended lymph node dissection (eLND, followed by radical prostatectomy. SLNs were detected in in vivo and in ex vivo samples. Diagnostic accuracy of sLND was assessed using eLND as the reference. SLNs were detected in all patients (detection rate 100%), with 447 sentinel lymph nodes SLNs (median 9, IQR 6–12) being identified and 966 LNs (median 18, IQR 15–23) being removed. Thirty-six percent (18/50) of patients had LN metastases (median 2, IQR 1–3). Magnetometer-guided sLND had 100% sensitivity, 97.0% specificity, 94.4% positive predictive value, 100% negative predictive value, 0.0% false negative rate, and 3.0% additional diagnostic value (LN metastases only in SLNs outside the eLND template). In vivo, one positive SLN/LN-positive patient was missed, resulting in a sensitivity of 94.4%. In conclusion, this new magnetic sentinel procedure has high accuracy for nodal staging in intermediate- and high-risk PCa. The reliability of intraoperative SLN detection using this magnetometer system requires verification in further multicentric studies. |
format | Online Article Text |
id | pubmed-7017225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70172252020-02-28 Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study Winter, Alexander Engels, Svenja Goos, Philipp Süykers, Marie-Christin Gudenkauf, Stefan Henke, Rolf-Peter Wawroschek, Friedhelm Cancers (Basel) Article Radioisotope-guided sentinel lymph node dissection (sLND) has shown high diagnostic reliability in prostate (PCa) and other cancers. To overcome the limitations of the radioactive tracers, magnetometer-guided sLND using superparamagnetic iron oxide nanoparticles (SPIONs) has been successfully used in PCa. This prospective study (SentiMag Pro II, DRKS00007671) determined the diagnostic accuracy of magnetometer-guided sLND in intermediate- and high-risk PCa. Fifty intermediate- or high-risk PCa patients (prostate-specific antigen (PSA) ≥ 10 ng/mL and/or Gleason score ≥ 7; median PSA 10.8 ng/mL, IQR 7.4–19.2 ng/mL) were enrolled. After the intraprostatic SPIONs injection a day earlier, patients underwent magnetometer-guided sLND and extended lymph node dissection (eLND, followed by radical prostatectomy. SLNs were detected in in vivo and in ex vivo samples. Diagnostic accuracy of sLND was assessed using eLND as the reference. SLNs were detected in all patients (detection rate 100%), with 447 sentinel lymph nodes SLNs (median 9, IQR 6–12) being identified and 966 LNs (median 18, IQR 15–23) being removed. Thirty-six percent (18/50) of patients had LN metastases (median 2, IQR 1–3). Magnetometer-guided sLND had 100% sensitivity, 97.0% specificity, 94.4% positive predictive value, 100% negative predictive value, 0.0% false negative rate, and 3.0% additional diagnostic value (LN metastases only in SLNs outside the eLND template). In vivo, one positive SLN/LN-positive patient was missed, resulting in a sensitivity of 94.4%. In conclusion, this new magnetic sentinel procedure has high accuracy for nodal staging in intermediate- and high-risk PCa. The reliability of intraoperative SLN detection using this magnetometer system requires verification in further multicentric studies. MDPI 2019-12-20 /pmc/articles/PMC7017225/ /pubmed/31877623 http://dx.doi.org/10.3390/cancers12010032 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Winter, Alexander Engels, Svenja Goos, Philipp Süykers, Marie-Christin Gudenkauf, Stefan Henke, Rolf-Peter Wawroschek, Friedhelm Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title | Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title_full | Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title_fullStr | Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title_full_unstemmed | Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title_short | Accuracy of Magnetometer-Guided Sentinel Lymphadenectomy after Intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles in Prostate Cancer: The SentiMag Pro II Study |
title_sort | accuracy of magnetometer-guided sentinel lymphadenectomy after intraprostatic injection of superparamagnetic iron oxide nanoparticles in prostate cancer: the sentimag pro ii study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017225/ https://www.ncbi.nlm.nih.gov/pubmed/31877623 http://dx.doi.org/10.3390/cancers12010032 |
work_keys_str_mv | AT winteralexander accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT engelssvenja accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT goosphilipp accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT suykersmariechristin accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT gudenkaufstefan accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT henkerolfpeter accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy AT wawroschekfriedhelm accuracyofmagnetometerguidedsentinellymphadenectomyafterintraprostaticinjectionofsuperparamagneticironoxidenanoparticlesinprostatecancerthesentimagproiistudy |